Karyopharm Therapeutics ( (KPTI) ) has provided an update.
Karyopharm Therapeutics has announced a change in the co-primary endpoint for its Phase 3 SENTRY trial in myelofibrosis, following FDA feedback. The trial will now use Absolute Total Symptom Score (Abs-TSS) instead of a ≥50% improvement, with the aim of better capturing patient benefits. This change, along with increased sample size and promising Phase 1 results, bolsters confidence in the trial’s potential. Karyopharm plans to report top-line results in the second half of 2025.
Find detailed analytics on KPTI stock on TipRanks’ Stock Analysis page.
